Abstract
The novel pandemic coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has challenged the medical community. While diagnostic and therapeutic efforts have been focused on respiratory complications of the disease, several ocular implications have also emerged. SARS-CoV-2 RNA has been found in tears of the infected patients, and reports suggest that the ocular surface could serve as a portal of entry and a reservoir for viral transmission. Clinically, COVID-19 has been associated with mild conjunctivitis, which can be the first and only symptom of the disease. Subtle retinal changes like hyperreflective lesions in the inner layers on optical coherence tomography (OCT), cotton-wool spots, and microhemorrhages have also been reported. In addition, COVID-19 has been associated with an increased incidence of systemic diseases like diabetes mellitus and Kawasaki disease, which are particularly relevant for ophthalmologists due to their potentially severe ocular manifestations. Several treatment strategies are currently under investigation for COVID-19, but none of them have been proved to be safe and effective to date. Intensive care unit patients, due to risk factors like invasive mechanical ventilation, prone position, and multiresistant bacterial exposure, may develop ocular complications like ocular surface disorders, secondary infections, and less frequently acute ischemic optic neuropathy and intraocular pressure elevation. Among the array of drugs that have shown positive results, the use of hydroxychloroquine and chloroquine has raised a concern due to their well-known retinal toxic effects. However, the risk of retinal toxicity with short-term high-dose use of antimalarials is still unknown. Ocular side effects have also been reported with other investigational drugs like lopinavir-ritonavir, interferons, and interleukin-1 and interleukin-6 inhibitors. The aim of this review was to summarize ophthalmological implications of SARS-CoV-2 infection to serve as a reference for eye care and other physicians for prompt diagnosis and management.
Highlights
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has led to a global epidemic with more than 4 million confirmed cases and 280,000 deaths worldwide far. e disease caused by severe acute respiratory syndrome (SARS)-CoV-2 has been named “COVID-19”.During December 2019, several cases of pneumonia of unknown origin were reported in Wuhan, the capital ofHubei Province in China [1]
Since SARS-CoV-2 may lead to respiratory failure, most of the diagnostic and therapeutic efforts are focused on the consequences of the infection in the respiratory tract
During the COVID-19 outbreak, conjunctivitis was reported as a manifestation of the disease and viral RNA was found in the patients’ tears
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has led to a global epidemic with more than 4 million confirmed cases and 280,000 deaths worldwide far. e disease caused by SARS-CoV-2 has been named “COVID-19” (where “CO” stands for corona, “VI” for virus, “D” for disease, and “19” indicates the year in which it occurred).During December 2019, several cases of pneumonia of unknown origin were reported in Wuhan, the capital ofHubei Province in China [1]. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has led to a global epidemic with more than 4 million confirmed cases and 280,000 deaths worldwide far. E disease caused by SARS-CoV-2 has been named “COVID-19” (where “CO” stands for corona, “VI” for virus, “D” for disease, and “19” indicates the year in which it occurred). During December 2019, several cases of pneumonia of unknown origin were reported in Wuhan, the capital of. A young ophthalmologist, Dr Li Wenliang, was the first physician to report similarities with severe acute respiratory syndrome (SARS). Dr Wenliang himself contracted the virus after treating an infected glaucoma patient and subsequently passed away [2]. E phylogenetic analysis suggests that bats may be the original host of the virus.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
